SILVER SPRING
Afrezza cleared for pediatric diabetes
- Sponsor
- MannKind Corporation $MNKD
- Drug
- Afrezza · insulin human
- Indication
- diabetes
FDA approved inhaled insulin Afrezza for children and adolescents aged 6+ with diabetes.
What this means
Afrezza is an inhaled insulin powder that works faster than traditional insulin shots by absorbing quickly through the lungs. Today FDA expanded its approval to include children and adolescents aged 6 and older with diabetes. This decision could offer younger patients a needle-free insulin option that may fit better into their daily routines.
Drug Watch — recent news on Afrezza
- Insulin human/insulin isophane human out-of-pocket cost in the U.S. from 2014 to 2023 - Statista
- MERP Annual Review Exposes How Manufacturer Labeling/Quality Issues Impact Medication Safety - ECRI
- Diabetes management: Cipla bags CDSCO regulatory nod for distribution, marketing of Afrezza (insulin... - Medical Dialogues
- CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India - Yahoo Finance
- Diabetes treatment in short supply affecting Milwaukee-area patients - WISN
Sponsor Watch — recent news on MannKind Corporation
- Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings
- Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
- These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Google Holds Top Rating
- The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss
- The Real Question Buried Inside Merck Stock's Premium Price